Holen Sie sich die Stockscreener-App
8.50
7.91%
-0.73
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Gene Therapy For Rare Disease Market Overall Study Report - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR
Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat
Baird cuts bluebird bio price target on near-term dilution - Investing.com
Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com
bluebird bio (NASDAQ:BLUE) Shares Down 13.4%Time to Sell? - MarketBeat
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Bluebird bio CEO Andrew Obenshain sells $405 in stock By Investing.com - Investing.com South Africa
Cell and Gene Therapy Market is Dazzling Worldwide and Forecast - openPR
Bluebird bio CEO Andrew Obenshain sells $405 in stock - Investing.com India
Growing Demand and Trends of Advanced Cell Therapy - openPR
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - MarketBeat
Bluebird bio Gets Nasdaq Noncompliance Notice - Marketscreener.com
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
BLUEbluebird bio, Inc. Latest Stock News & Market Updates - StockTitan
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H - Yahoo Finance
CMS enters agreement with Vertex, bluebird to improve access to gene therapies - Reuters
bluebird bio announces 1-for-20 reverse stock split; shares tumble - MSN
Bluebird Bio announces 1-for-20 reverse stock split - TipRanks
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program - Benzinga
BLUE (bluebird bio) 3-Year FCF Growth Rate : 34.80% (As of Sep. 2024) - GuruFocus.com
Bluebird and Vertex's sickle cell gene therapies to kick off new Medicaid access model - Endpoints News
CMS rolls out new payment model for Vertex, bluebird gene therapies (NASDAQ:BLUE) - Seeking Alpha
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire
bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat
Gene Therapy And Secondary Malignancies: Integration Site Analysis Can Only Be Part Of The Answer - News & Insights
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports - FiercePharma
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies - BioSpace
Gene Therapy: Lyfgenia Voucher Denial Puts Sickle Cell Treatment At Risk, Bluebird Bio Says - News & Insights
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy - Yahoo Finance
FDA investigating safety risks of bluebird's Skysona - MSN
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action - Reuters
FDA investigating safety risks of bluebird's Skysona (NASDAQ:BLUE) - Seeking Alpha
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Adrenoleukodystrophy Treatment Market Global Share, Trends, - openPR
Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
bluebird bio says seeking more cash to achieve cash flow break-even - MSN
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
B of A Securities Downgrades bluebird bio (BLUE) - MSN
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors Australia
Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):